{'fraction_non_alphanumeric': 0.02854006586169045, 'fraction_numerical': 0.005488474204171241, 'mean_word_length': 4.96078431372549, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
FUSF Final Report: Accessibility and Benefit of FUS treatment for inoperable Lung Cancer Patients, a retrospective Analysis

Lung cancer (LC) is the mortal leading tumor entity, with increasing incidence in female. Curative treatment is achieved by surgical resection, but 70% of patients are inoperable at diagnosis [2]. HIFU as a non-invasive treatment is not applicable in ventilated lung. By using One Lung Flilling (OLF) acoustic access to central tumors can be generated without lung damage [3]. Our work showed the feasibility for FUS ablation using OLF [4] which could lead to a novel a novel, minimal invasive treatment modality for lung cancer (LC). It remains unclear which amount of patients are eligible to OLF and therefore FUS. Therefore a retrospective analysis of inoperable LC cases was performed to identify LC entities preferably fit for OLF and show strength as well as limitations for FUS.